Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the highest tolerated dose, safety and activity of HCD122 in patients with Multiple Myeloma who are relapsed after receiving prior treatment.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Antibodies; Antibodies, Monoclonal; Immunoglobulins

Criteria

Inclusion Criteria:

• Clinical Diagnosis of MM requiring treatment

• Refractory or Relapsed Disease

• At least one prior treatment regimen

• Male or Female

• >18 years of age

Exclusion Criteria:

• Prior Allogeneic bone marrow transplant (prior autologous transplant allowed)

• Intracranial disease or epidural disease

• Clinically significant cardiac dysfunction or other significant organ dysfunction